Scribe Therapeutics announced the pricing of its upsized initial public offering, selling 8.58 million shares at $15 apiece, raising $128.7 million to advance its in vivo CRISPR technologies for patients suffering from highly prevalent diseases.
Scribe’s focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. Its lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene, resulting in significant and durable reduction of LDL-C levels. The company expects to report initial data during the first half of 2027 from an Australian trial in adults with an increased risk of ASCVD.
Scribe is backed by more than $180 million in partnership payments from Sanofi and Eli Lilly. In addition to the shares being sold in the IPO, Scribe has agreed to sell 500,000 shares of its common stock in a concurrent private placement to Sanofi.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!